KRFK (TFA)
KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach[1].
Product Specifications
UNSPSC
12352209
Target
TGF-β Receptor
Type
Peptides
Related Pathways
TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/krfk-tfa.html
Purity
99.90
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCCN)C(O)=O)=O)=O)[C@H](CCCCN)N.OC(C(F)(F)F)=O.[x]
Molecular Formula
C27H47N9O5.xC2HF3O2
Molecular Weight
577.73 (free base)
References & Citations
[1]Soriano-Romaní L, et al. Topical Application of TGF-β-Activating Peptide, KRFK, Prevents Inflammatory Manifestations in the TSP-1-Deficient Mouse Model of Chronic Ocular Inflammation. Int J Mol Sci. 2018 Dec 20;20 (1) :9.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
